Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
B‑cell
B‑cell chronic lymphocytic leukemia
T‑cell
bendamustine hydrochloride
cell cycle
cell death
immunomodulation
lymphocytes
non‑Hodgkin lymphoma
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
25
01
2022
accepted:
01
04
2022
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B‑cell non‑Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematological malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine‑mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncology, its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune‑modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug.
Identifiants
pubmed: 35506458
doi: 10.3892/or.2022.8325
pii: 114
pmc: PMC9100486
doi:
pii:
Substances chimiques
Antineoplastic Agents
0
Nitrogen Mustard Compounds
0
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Opin Oncol. 2019 Sep;31(5):374-379
pubmed: 31233483
Leukemia. 2019 Apr;33(4):969-980
pubmed: 30315239
J Clin Oncol. 2009 Mar 20;27(9):1492-501
pubmed: 19224851
J Clin Oncol. 2019 Apr 20;37(12):984-991
pubmed: 30811293
Bone Marrow Transplant. 2019 Dec;54(12):2027-2038
pubmed: 31190006
Am J Hematol. 2021 Jul 1;96(7):E243-E246
pubmed: 33811767
Blood Cells Mol Dis. 2012 Jan 15;48(1):68-75
pubmed: 22036761
Croat Med J. 2021 Oct 31;62(5):455-463
pubmed: 34730885
Br J Haematol. 2020 May;189(4):684-688
pubmed: 32011729
Blood. 2018 Jan 25;131(4):417-420
pubmed: 29196411
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Am J Transl Res. 2013;5(1):36-46
pubmed: 23390564
Int Immunopharmacol. 2016 Oct;39:273-279
pubmed: 27500457
Leuk Lymphoma. 2016;57(4):766-82
pubmed: 26592922
Oncologist. 2019 Aug;24(8):1035-e623
pubmed: 31073022
J Thorac Oncol. 2014 Apr;9(4):559-62
pubmed: 24736081
Br J Haematol. 2016 Oct;175(2):281-289
pubmed: 27448091
Br J Haematol. 2018 Apr;181(2):215-228
pubmed: 29532919
Lancet Oncol. 2016 Aug;17(8):1081-1093
pubmed: 27345636
Cancer. 2007 Aug 15;110(4):861-6
pubmed: 17599772
J Clin Oncol. 2013 Feb 1;31(4):456-60
pubmed: 23248254
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Front Immunol. 2021 Jun 24;12:699128
pubmed: 34249005
Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88
pubmed: 34508254
Br J Haematol. 2020 May;189(3):e86-e90
pubmed: 32048731
J Clin Oncol. 2008 Jan 10;26(2):204-10
pubmed: 18182663
Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):452-7
pubmed: 21189660
Oncotarget. 2016 Feb 2;7(5):5507-20
pubmed: 26701728
Clin Cancer Res. 2009 Dec 15;15(24):7456-7461
pubmed: 19996200
Cancers (Basel). 2021 Apr 03;13(7):
pubmed: 33916711
Front Immunol. 2021 Oct 25;12:738915
pubmed: 34759921
Semin Hematol. 2011 Apr;48 Suppl 1:S4-11
pubmed: 21530771
Lancet Oncol. 2016 Jan;17(1):57-66
pubmed: 26655425
J Clin Oncol. 2009 Sep 10;27(26):4378-84
pubmed: 19652068
Blood Cancer J. 2019 Dec 11;9(12):100
pubmed: 31827067
J Pediatr Hematol Oncol. 2014 May;36(4):e212-8
pubmed: 24072240
PLoS One. 2012;7(6):e40342
pubmed: 22768280
Clin Cancer Res. 2008 Nov 1;14(21):6907-15
pubmed: 18980985
Blood Cancer J. 2015 Oct 23;5:e362
pubmed: 26495859
Clin Infect Dis. 2019 Jan 7;68(2):247-255
pubmed: 29800121
Bone Marrow Transplant. 2020 Jun;55(6):1076-1084
pubmed: 31953532
Cancer Chemother Pharmacol. 2013 May;71(5):1183-90
pubmed: 23430121
Semin Hematol. 2011 Apr;48 Suppl 1:S12-23
pubmed: 21530768
Leuk Lymphoma. 2016;57(3):512-9
pubmed: 26696321
Blood Adv. 2020 Apr 28;4(8):1756-1759
pubmed: 32343794
Ther Adv Med Oncol. 2021 Oct 19;13:17588359211042301
pubmed: 34691243
J Clin Oncol. 2020 Sep 1;38(25):2849-2861
pubmed: 32459600
J Clin Oncol. 2018 Aug 10;36(23):2395-2404
pubmed: 29856692
Clin Cancer Res. 2008 Jan 1;14(1):309-17
pubmed: 18172283
Leukemia. 2002 Oct;16(10):2096-105
pubmed: 12357363
Blood Adv. 2022 Jan 25;6(2):533-543
pubmed: 34749395
Ann Hematol. 2022 Jan;101(1):209-211
pubmed: 33392703
Nat Rev Cancer. 2012 Jan 12;12(2):104-20
pubmed: 22237395
Oncoimmunology. 2020 Apr 30;9(1):1758011
pubmed: 32391190
J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9
pubmed: 12458340
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
Cancer Lett. 2013 Jul 28;335(2):343-50
pubmed: 23459296
J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53
pubmed: 17653574
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Leuk Lymphoma. 2020 Dec;61(13):3188-3197
pubmed: 32762271
Drugs R D. 2013 Mar;13(1):17-28
pubmed: 23322528
Lancet Oncol. 2018 Feb;19(2):257-266
pubmed: 29276022
Br J Haematol. 2021 Jun;193(6):1123-1133
pubmed: 33973233
Allergol Int. 2015 Jan;64(1):109-11
pubmed: 25572568
Drugs. 2012 Oct 1;72(14):1929-50
pubmed: 22950536
Br J Haematol. 2019 Mar;184(6):957-968
pubmed: 30548597
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Clin Cancer Res. 2013 Nov 15;19(22):6313-21
pubmed: 24097860
Blood Adv. 2019 Oct 22;3(20):3132-3135
pubmed: 31648328
BMC Cancer. 2018 Jul 9;18(1):729
pubmed: 29986691
Pharmacogenomics J. 2015 Aug;15(4):363-71
pubmed: 25582574
Ann Hematol. 2014 Nov;93(11):1879-87
pubmed: 24951124
Drugs. 2010 Sep 10;70(13):1703-18
pubmed: 20731477
PLoS One. 2012;7(12):e51681
pubmed: 23284739
J Clin Oncol. 2018 Aug 1;36(22):2259-2266
pubmed: 29584548
Clin Adv Hematol Oncol. 2011 Aug;9(8 Suppl 19):1-11
pubmed: 22362008
Clin Cancer Res. 2014 Apr 1;20(7):1814-22
pubmed: 24486595
Blood. 2012 May 31;119(22):5088-103
pubmed: 22403259
EClinicalMedicine. 2020 Oct;27:100549
pubmed: 33073216
Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F330-8
pubmed: 25477469
Clin Med Insights Oncol. 2011;5:145-56
pubmed: 21695099
Br J Haematol. 2017 Mar;176(5):759-769
pubmed: 27992063
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
pubmed: 21527953
Br J Haematol. 2012 Oct;159(1):67-77
pubmed: 22861163
Open Med (Wars). 2021 Apr 21;16(1):672-682
pubmed: 33981851
Br J Haematol. 2016 Jul;174(1):102-16
pubmed: 27030315
BMC Infect Dis. 2019 Oct 22;19(1):881
pubmed: 31640581
Lancet Haematol. 2017 Jan;4(1):e15-e23
pubmed: 27927586
Hemasphere. 2020 Jun 08;4(3):e401
pubmed: 32647803
Hematol Oncol. 2017 Dec;35(4):424-431
pubmed: 27734524
Hemasphere. 2018 Apr 25;2(3):e39
pubmed: 31723767
Ann Oncol. 2000 Jun;11(6):729-34
pubmed: 10942063
Br J Haematol. 2017 Jul;178(2):250-256
pubmed: 28419413
Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54
pubmed: 25829094
J Cancer Res Clin Oncol. 2003 May;129(5):316-9
pubmed: 12756557
PLoS One. 2014 Mar 13;9(3):e90675
pubmed: 24626203